Trade Alexion Pharmaceuticals, Inc. - ALXN shares price

1m
5m
15m
30m
1H
4H
1D
1W
Open on web platform

Market info

Min traded quantity:
1
Full name:
Alexion Pharmaceuticals, Inc.
Currency:
USD
Margin:
5%
Stock exchange:
United States of America
Long position overnight fee
-0.0203%
Short position overnight fee
-0.0102%

Trading hours (UTC)

Mon - Fri:
13:30 - 20:00

ALXN

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. In addition, the company conducts Phase III clinical trials for ALXN 1210 (IV) that is in Phase III clinical trials for the treatment of PNH and aHUS; ALXN1210 (Subcutaneous), which is in Phase I for PNH and aHUS; and Soliris (eculizumab) for the treatment of myasthenia gravis and neuromyelitis optica spectrum disorder. Further, it develops cPMP (cyclic Pyranopterin Monophosphate) (ALXN 1101) for molybdenum cofactor deficiency disease type A; and Samalizumab (ALXN6000), an immunomodulatory humanized monoclonal antibody. The company serves distributors, pharmacies, hospitals, hospital buying groups, and other healthcare providers in the United States, Europe, the Asia Pacific, and internationally. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc. to use drug-delivery technology in the development of subcutaneous formulations for its portfolio of products. The company was founded in 1992 and is headquartered in New Haven, Connecticut.
White Paper Declaration

You might be interested in

A world first

Our advanced web platform is the world’s first regulated tokenised assets exchange.

Crypto as collateral

Trade the global financial markets using Bitcoin or Ethereum.

Security as priority

Authorised by the High Technology Park of Belarus, the European blockchain regulator, the safety of your holdings is guaranteed.

Technical indicators

Keep an eye on your positions with over 75 advanced charts, price analysis and price alerts.

Control your capital

Use stop-loss and take-profit orders to keep what you earn.

Use the world’s first regulated tokenised assets exchange to build a diverse investment portfolio with your crypto holdings. Make your deposits in Bitcoin or Ethereum to trade global financial instruments with competitive leverage and tight spreads. Currency.com keeps your holdings secure and accessible at a glance.

VISA MASTERCARD Yandex Money WIRE Faster payments SEPA PCI BTC ETH